Payment overview · 2025
General Payments
$3,473.90
145 reported records · 21 companies
Healthcare provider profile · identity verified
Eric John Klein, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OLYMPIA, WA · NPI 1083612568
Verified facts
What the public records show
CMS Open Payments records show Eric John Klein, MD received $3,473.90 in general payments during 2025 across 145 reported records.
Amgen Inc. accounted for 15.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 225 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $540.28 | 15.6% | 26 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $519.85 | 15.0% | 25 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $412.46 | 11.9% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $303.17 | 8.7% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $281.32 | 8.1% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $238.87 | 6.9% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $189.45 | 5.5% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $158.89 | 4.6% | 7 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$145.35 | 4.2% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $108.77 | 3.1% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $108.01 | 3.1% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $107.98 | 3.1% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $98.14 | 2.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $86.90 | 2.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.32 | 1.2% | 2 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $26.22 | 0.8% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $24.81 | 0.7% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $24.24 | 0.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.12 | 0.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.26 | 0.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.49 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,452.93 | 143 |
| Education | $20.97 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $519.85 | 25 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $489.24 | 23 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $412.46 | 14 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $292.97 | 14 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $281.32 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $267.59 | 13 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $261.98 | 11 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $261.98 | 11 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $226.34 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $158.89 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $149.17 | 6 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $145.35 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $138.05 | 7 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $108.77 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $108.01 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $104.30 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $98.14 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $66.76 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $61.07 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $54.78 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $46.62 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $46.04 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $43.36 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $43.32 | 2 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $26.22 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.26 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 89 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 77 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 172 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 225 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 116 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 14 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
77 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
172 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
172 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
225 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
116 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
89 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 543 | 146 |
| Amlodipine Besylate | Amlodipine Besylate | 302 | 77 |
| Ezetimibe | Ezetimibe | 300 | 84 |
| Mounjaro | Tirzepatide | 225 | 29 |
| Metformin Hcl | Metformin Hcl | 221 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 216 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 210 | 53 |
| Omeprazole | Omeprazole | 197 | 60 |
| Lisinopril | Lisinopril | 192 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 46 |
| Jardiance | Empagliflozin | 172 | 31 |
| Celecoxib | Celecoxib | 171 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 161 | 44 |
| Losartan Potassium | Losartan Potassium | 130 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 124 | 36 |
| Ozempic | Semaglutide | 116 | 23 |
| Simvastatin | Simvastatin | 96 | 28 |
| Allopurinol | Allopurinol | 90 | 24 |
| Eliquis | Apixaban | 89 | 22 |
| Spironolactone | Spironolactone | 84 | 20 |
| Gabapentin | Gabapentin | 83 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 27 |
| Farxiga | Dapagliflozin Propanediol | 77 | 16 |
| Glimepiride | Glimepiride | 68 | 16 |
| Prednisone | Prednisone | 67 | 39 |
| Repatha Sureclick | Evolocumab | 67 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 64 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 21 |
| Meloxicam | Meloxicam | 58 | 16 |
| Bupropion Xl | Bupropion Hcl | 57 | 17 |
| Furosemide | Furosemide | 51 | 20 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 51 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 16 |
| Alprazolam | Alprazolam | 49 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 48 | 15 |
| Sertraline Hcl | Sertraline Hcl | 42 | 16 |
| Cefuroxime | Cefuroxime Axetil | 41 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 40 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | 12 |
| Cephalexin | Cephalexin | 33 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 17 |
| Valacyclovir | Valacyclovir Hcl | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | 13 |
| Torsemide | Torsemide | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Methotrexate | Methotrexate Sodium | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 31 | suppressed |
| Carvedilol | Carvedilol | 30 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | 12 |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 15 |
| Potassium Chloride | Potassium Chloride | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 15 |
| Finasteride | Finasteride | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Humira(Cf) Pen | Adalimumab | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,473.90 · 145 records | Amgen Inc. | AREXVY, Arikayce, Brinsupri, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, ISTURISA, JARDIANCE, Kerendia, Korlym, LEQVIO, MINIMED 780G, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PROLIA, QULIPTA, REPATHA, SHINGRIX, TRELEGY ELLIPTA, TWIIST, UBRELVY, Wegovy, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error